March 2, 2026/
Version 29.0, released in March 2026, introduces significant terminology updates, including new terms, revised hierarchies, changes to Standardised MedDRA Queries (SMQs), and important modifications to medication...
ALVigiLance is a dedicated pharmacovigilance platform designed to support the healthcare team in ensuring safer medication use. Our mission is simple yet vital: to provide trusted insights, practical tools, and up-to-date resources that empower healthcare professionals to identify, prevent, and manage adverse drug reactions (ADRs).
Simplified, practical guides on drug safety and monitoring.
Real-world examples to strengthen your clinical decision-making.
Summaries of global drug warnings and regulatory actions.
Strategies for adverse event reporting, risk management, and patient counseling.
To create a proactive community of healthcare providers who champion medication safety and improve patient outcomes through shared knowledge and vigilance.
Medication safety is everyone’s responsibility. Explore, learn, and engage with ALVigiLance — because together, we can reduce risks and save lives.
Version 29.0, released in March 2026, introduces significant terminology updates, including new terms, revised hierarchies, changes to Standardised MedDRA Queries (SMQs), and important modifications to medication...
This article provides a comprehensive medical overview of rare diseases, with a dual focus: first, on drug-induced rare diseases as adverse reactions, and second, on the critical risk-benefit calculus for...
From a pharmacovigilance standpoint, Ramadan represents a period of systematic medication schedule disruption, altered drug pharmacokinetics, and increased vulnerability to adverse drug reactions (ADRs).
